PE20000646A1 - COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY - Google Patents

COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY

Info

Publication number
PE20000646A1
PE20000646A1 PE1999000528A PE00052899A PE20000646A1 PE 20000646 A1 PE20000646 A1 PE 20000646A1 PE 1999000528 A PE1999000528 A PE 1999000528A PE 00052899 A PE00052899 A PE 00052899A PE 20000646 A1 PE20000646 A1 PE 20000646A1
Authority
PE
Peru
Prior art keywords
oxo
phenyl
combination therapy
tartrate salt
musculoskeletal
Prior art date
Application number
PE1999000528A
Other languages
Spanish (es)
Inventor
Hua Zhu Ke
David Duane Thompson
Mei Li
Lydia Codetta Pan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20000646A1 publication Critical patent/PE20000646A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN MODULADOR DEL RECEPTOR DE ESTROGENOS SELECTIVO (SERM) TAL COMO (-)-CIS-6-FENIL-5-(4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL)-5,6,7,8-TETRAHIDRONAFTALEN-2-OL O SU SAL D-TARTRATO; b)UN SECRETAGOGO DE LA HORMONA DEL CRECIMIENTO (GHS) TAL COMO 2-AMINO-N-(2-(3a(R)-BENCIL-2-METIL-3-OXO-2,3,3a,4,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDIN-5-IL)-1(R)-BENCILOXIMETIL-2-OXO-ETIL)-ISOBUTILAMINA O SU SAL L-TARTRATO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA FRAGILIDAD MUSCULOESQUELETICA, OSTEOPOROSIS, PERIODONTITIS, CURACION OSEA DESPUES DE UNA RECONSTRUCCION MAXILAR O MANDIBULAR, FRACTURA OSEAREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING a) A SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) SUCH AS (-) - CIS-6-PHENYL-5- (4- (2-PYRROLIDIN-1-IL-ETOXY) -PHENYL ) -5,6,7,8-TETRAHIDRONAFTALEN-2-OL OR ITS D-TARTRATE SALT; b) A SECRETAGOG OF GROWTH HORMONE (GHS) SUCH AS 2-AMINO-N- (2- (3a (R) -BENZYL-2-METHYL-3-OXO-2,3,3a, 4,6,7 -HEXAHYDRO-PYRAZOLO [4,3-c] PYRIDIN-5-IL) -1 (R) -BENZYLOXIMETHYL-2-OXO-ETHYL) -ISOBUTYLAMINE OR ITS L-TARTRATE SALT. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF MUSCULOSKELETAL FRAGILITY, OSTEOPOROSIS, PERIODONTITIS, BONE HEALING AFTER A MAXILLARY OR MANDIBULAR RECONSTRUCTION, BONE FRACTURE

PE1999000528A 1998-06-16 1999-06-15 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY PE20000646A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
PE20000646A1 true PE20000646A1 (en) 2000-08-05

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000528A PE20000646A1 (en) 1998-06-16 1999-06-15 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY

Country Status (30)

Country Link
EP (1) EP1087764A1 (en)
JP (1) JP2002518326A (en)
KR (1) KR20010052852A (en)
CN (1) CN1301160A (en)
AP (1) AP9901582A0 (en)
AR (1) AR018869A1 (en)
AU (1) AU4054799A (en)
BG (1) BG105041A (en)
BR (1) BR9911324A (en)
CA (1) CA2335134A1 (en)
CO (1) CO5070587A1 (en)
EA (1) EA200001186A1 (en)
GT (1) GT199900087A (en)
HN (1) HN1999000097A (en)
HR (1) HRP20000859A2 (en)
HU (1) HUP0102505A3 (en)
ID (1) ID27599A (en)
IL (1) IL138630A0 (en)
IS (1) IS5691A (en)
MA (1) MA26652A1 (en)
NO (1) NO20006312D0 (en)
OA (1) OA11505A (en)
PA (1) PA8475901A1 (en)
PE (1) PE20000646A1 (en)
PL (1) PL344981A1 (en)
SK (1) SK18912000A3 (en)
TN (1) TNSN99124A1 (en)
TR (1) TR200003544T2 (en)
WO (1) WO1999065486A1 (en)
ZA (1) ZA993975B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
DE60124616T2 (en) 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatic cleavage of selective modulators of the estrogen receptor
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS

Also Published As

Publication number Publication date
HUP0102505A3 (en) 2002-12-28
AR018869A1 (en) 2001-12-12
AP9901582A0 (en) 1999-06-30
PA8475901A1 (en) 2000-05-24
ID27599A (en) 2001-04-12
KR20010052852A (en) 2001-06-25
WO1999065486A1 (en) 1999-12-23
OA11505A (en) 2004-05-07
BG105041A (en) 2001-08-31
AU4054799A (en) 2000-01-05
SK18912000A3 (en) 2001-10-08
IS5691A (en) 2000-10-27
MA26652A1 (en) 2004-12-20
HUP0102505A2 (en) 2001-11-28
IL138630A0 (en) 2001-10-31
BR9911324A (en) 2001-04-03
NO20006312L (en) 2000-12-12
HN1999000097A (en) 1999-11-03
PL344981A1 (en) 2001-11-19
CA2335134A1 (en) 1999-12-23
NO20006312D0 (en) 2000-12-12
CN1301160A (en) 2001-06-27
EP1087764A1 (en) 2001-04-04
JP2002518326A (en) 2002-06-25
HRP20000859A2 (en) 2001-04-30
TNSN99124A1 (en) 2005-11-10
TR200003544T2 (en) 2001-04-20
CO5070587A1 (en) 2001-08-28
ZA993975B (en) 2000-12-15
EA200001186A1 (en) 2001-06-25
GT199900087A (en) 2000-12-07

Similar Documents

Publication Publication Date Title
PE20020722A1 (en) DERIVATIVES OF GLUCOPYRANOSILOXIPYRAZOL AS AN INHIBITOR OF HUMAN SGLT2
ECSP066313A (en) DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS
ECSP066315A (en) DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS
SE9903760D0 (en) New compounds
ECSP066312A (en) PIRIDILO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
BG107697A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
PA8493701A1 (en) COMPOUNDS TO TREAT OBESITY
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
BR0015624A (en) Use of a compound, compound, pharmaceutical composition, and method of treatment or prophylaxis of human diseases or conditions
NO20022442D0 (en) Medicines for diseases related to reduction in bone mass
DE60113032D1 (en) Glucocorticoid receptor modulators
CU23241B7 (en) 2-PHENYL-1- (4 (2-AMINOETOXI) -BENZIL) -INDOL IN COMBINATION WITH STROGENS
BR0316877A (en) Aryl-quinazoline / aryl-2-amino-phenyl methanone derivatives that promote parathyroid hormone release
DE60120077D1 (en) Modulators of the glucocorticoid receptor
BRPI0417621A (en) continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen for the treatment of conditions with low bone mass
PE20000646A1 (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
PE20000644A1 (en) THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND PARATHYROID HORMONE
PE20030944A1 (en) INDOLYL-UREA DERIVED FROM THENOPYRIDINES USEFUL AS ANTIANGIOGENIC AGENTS AND PROCEDURES FOR THEIR USE
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
ECSP044961A (en) ACID N- (5-CHLOROSALICILOIL) -8-AMINOCAPRILICO AS AN ORAL SUPPLY AGENT FOR PARTIROID HORMONE FRAGMENTS
PE122699A1 (en) VITRONECTIN RECEPTOR ANTAGONISTS
BRPI0410050A (en) method of treatment or prophylaxis of psychotic disorders, disorders of intellectual impairment or diseases or conditions in which alpha-nicotinic receptor modulation is beneficial, pharmaceutical composition, method of treatment or prophylaxis of diseases, use of a compound, compound, and , method of preparing a compound
PE20000633A1 (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY

Legal Events

Date Code Title Description
FD Application declared void or lapsed